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From February 1, 2005, to January 31, 2006, we
screened 115 adults for avian influenza (H5N1) and
influenza A if admitted to an intensive care unit with pneu-
monia. Using reverse transcription-PCR, viral culture, and
serologic testing for anti-H5 antibody, we identified 8 (7%)
patients with influenza A (H3N2); none had H5N1.
Estimated costs for H5N1 screening were $7,375.
T
he ongoing avian influenza (H5N1) pandemic poses
risks to both human and animal health (1–5). The
potential exists for cross-species transmission of avian
influenza to humans and subsequent reassortment of avian
and human influenza viruses in coinfected persons (6).
Although atypical presentations of avian influenza (H5N1)
have been reported (7,8), in most H5N1 case-patients
pneumonia was the primary condition (3,4). To assess the
prevalence of avian influenza (H5N1) and influenza A
pneumonia, we screened adults admitted to a medical
intensive care unit (ICU) with community-acquired pneu-
monia (CAP) for H5N1 and calculated the cost estimates
for H5N1 screening in a tertiary care center of an H5N1-
endemic area in Thailand.
The Study 
Thammasat University Hospital is a 450-bed tertiary
care center with an 8-bed intensive care unit (ICU)
equipped with central air-conditioning and 2 isolation
rooms. The hospital serves a 150-km radius referral base in
central Thailand and has 980 healthcare workers (HCWs).
Annual influenza vaccination was not routinely offered to
HCWs. During the study period, 2 confirmed cases of
H5N1 occurred within 150 km of our hospital.
All adults admitted to the ICU with CAP between
February 1, 2005, and January 31, 2006, were eligible for
enrollment. Tracheal aspirates were collected for H5N1
testing, with reverse transcription (RT)-PCR, and viral cul-
ture. In patients <60 years with >14 days survival posthos-
pitalization, paired acute-phase and convalescent-phase
serum specimens were collected for identifying anti-H5
antibody. Acute-phase serum specimens for determining
anti-H5 antibody were obtained within 1 week of symp-
toms, while convalescent-phase serum specimens were
obtained >14 days after the acute-phase specimens were
collected. Data collection included demographic character-
istics, clinical data, and the costs associated with H5N1
screening. The diagnosis of CAP was defined according to
the criteria recommended by the American Thoracic
Society (9). Patients who were hospitalized for >2 days
and in whom pneumonia developed were excluded from
this study. The current Thai national surveillance definition
for probable avian influenza (H5N1) included the follow-
ing: 1) presence of fever (>38°C), and 2) influenza-like ill-
ness, and 3) exposure to sick poultry or residence in the
disease-endemic areas with excess poultry death rates, and
4) radiographic evidence of severe CAP without an identi-
fied etiologic agent (10).
Viral cultures for H5N1 and influenza A, as part of
screening, were incubated in Madin-Darby canine kidney
(MDCK) cell monolayers at the Thai National Institute of
Health. Tracheal aspirate specimens were tested by an RT-
PCR assay specific for the hemagglutinin gene of H5 (11).
If a specimen yielded a positive H5 band, the specimens
were confirmed by different RT-PCR primers and by real-
time RT-PCR (12). All serum samples were tested for H5-
specific antibody by a microneutralization (micro-NT)
test. The reactive samples underwent confirmatory
immunofluorescence testing by using H5-transfected 293
T cells as the test antigen (13). Influenza A/Thailand/
1(KAN-1)/2004 (H5N1) was used as the test virus. Acute-
phase and convalescent-phase serum samples were serial-
ly diluted from 1:20 to 1:80. On the basis of previously
established criteria, a positive test was defined as a neutral-
izing antibody titer >80 with a confirmatory immunofluo-
rescence assay (14). Adults >60 years of age were
excluded from the serologic tests because the H5N1 micro-
NT was previously reported to be less specific in this
population (14).
Laboratory diagnostic costs (RT-PCR for H5N1, viral
culture, and paired acute- and convalescent-phase serum
samples for anti-H5 antibody) for each patient were
obtained from line-item reports of the hospital’s fiscal sys-
tem. All costs in Thai baht currency were converted to US
dollars at an exchange rate of 40 bahts per 1 US dollar. The
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One hundred fifteen of 450 patients (25%) met the def-
inition of CAP and consented to study participation. The
patient characteristics are summarized in Table 1. None of
the 115 patients had tracheal aspirates positive for H5N1;
also not positive were any serologic test results from the 42
patients (37%) who were <60 years old and survived >14
days after hospitalization. We were unable to calculate the
prevalence of anti-H5 antibody in this sample, given that
only 37% of participants underwent complete diagnostic
antibody testing.
Eighteen patients (16%) met the Thai national surveil-
lance definition of probable H5N1, yet tracheal aspirates
and serologic test results were negative for H5N1. The
median time from initial symptoms to hospitalization was
4 days (range 2–8 days), and all 18 were appropriately
placed on contact and droplet isolation; the mean duration
of isolation was 9 days (range 4–13 days).
Although 48 (42%) of the 115 participants had no iden-
tified etiologic agent associated with CAP, Streptococcus
pneumoniae (n = 39; 34%), influenza A (H3N2) (n = 8;
7%), Staphylococcus aureus (n = 7; 6%), and Haemophilus
influenzae (n = 6; 5%) were the most common microorgan-
isms detected. In addition, 19 patients (n = 19; 16%) had
gram-negative microorganisms detected. All patients with
H3N2 pneumonia were promptly transferred to an isola-
tion room; 5 (62.5%) had dual infections of H3N2 and S.
aureus (n = 3), Klebsiella pneumoniae (n = 1) and
Pseudomonas species (n = 1), while CAP due to H3N2
developed in 3 (37.5%). Of 18 patients who met the defi-
nition of probable H5N1, 8 (44.5%) had S. pneumoniae
infection, 4 (22.5%) had S. aureus infection, 2 (11%) had
H3N2 infection, 2 (11%) had Burkholderia pseudomallei
infection, and 2 (11%) had no other agent detected. No
CAP patients had anti-H5 antibody seroconversion,
although 1 participant had evidence of positive anti-H5
antibody with low titer (10) during the recovery phase.
This patient lived in an avian influenza (H5N1)–endemic
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reported no exposure to sick poultry or persons with sus-
pected avian influenza (H5N1) infection. His tracheal cul-
ture yielded S. pneumoniae. All patients with H3N2
pneumonia sought treatment between late March and
November, the influenza Aseason in Thailand, and were in
contact and droplet isolation for a mean of 7 days (range
1–12 days). The all-cause mortality rate was 10% (Table
1). The cost estimates were $7,375 for H5N1 screening,
$23,328 for subsequent infection control measures, $300
for annual influenza vaccination of ICU HCWs, and
$9,800 for annual influenza vaccination of the entire hos-
pital staff (Table 2). The perceived benefits of vaccination
of all ICU HCWs included reduced risk for influenza
among vaccinated HCWs and reduced risk for influenza
transmission to at-risk ICU patients.
Conclusions
Our study findings are relevant to the prevention and
control of spread of both H5N1 and H3N2. The relatively
high prevalence of H3N2 (7%) among our CAP patients
suggests that HCWs in ICUs in disease-endemic regions
are at high-risk of acquiring influenza A. An annual
influenza vaccination occupational health program, similar
to those in developed countries, along with targeted case
identification of patients at high risk for influenza pneumo-
nia, may help minimize the clinical and economic conse-
quences of influenza A transmission. Although the
importance of a single patient’s positive low-titer anti-H5
antibody in this study was uncertain, this finding may rep-
resent a false-positive test, given that the patient had no
notable exposure to sick poultry or to persons with sus-
pected H5N1 infection. Additionally, the fact that all 18
probable case-patients had negative results for H5N1 sug-
gests that the current Thai surveillance definition may need
further refinement. Given the potential for reassortment of
H5N1 and influenza A in a coinfected person residing in a
disease-endemic setting, additional H5N1 screening, along
with cost-effectiveness studies, are warranted before this
screening strategy is adapted to H5N1-endemic areas.
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